Nature Communications (Mar 2023)
Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer
- Tian-mei Zeng,
- Guang Yang,
- Cheng Lou,
- Wei Wei,
- Chen-jie Tao,
- Xi-yun Chen,
- Qin Han,
- Zhuo Cheng,
- Pei-pei Shang,
- Yu-long Dong,
- He-ming Xu,
- Lie-ping Guo,
- Dong-sheng Chen,
- Yun-jie Song,
- Chuang Qi,
- Wang-long Deng,
- Zhen-gang Yuan
Affiliations
- Tian-mei Zeng
- Department of Oncology, Eastern Hepatobiliary Surgery Hospital, Second military medical univercity
- Guang Yang
- Department of Oncology, Eastern Hepatobiliary Surgery Hospital, Second military medical univercity
- Cheng Lou
- Department of Oncology, Eastern Hepatobiliary Surgery Hospital, Second military medical univercity
- Wei Wei
- Department of Oncology, Eastern Hepatobiliary Surgery Hospital, Second military medical univercity
- Chen-jie Tao
- Department of Oncology, Eastern Hepatobiliary Surgery Hospital, Second military medical univercity
- Xi-yun Chen
- Department of Oncology, Eastern Hepatobiliary Surgery Hospital, Second military medical univercity
- Qin Han
- Department of Oncology, Eastern Hepatobiliary Surgery Hospital, Second military medical univercity
- Zhuo Cheng
- Department of Oncology, Eastern Hepatobiliary Surgery Hospital, Second military medical univercity
- Pei-pei Shang
- Department of Oncology, Eastern Hepatobiliary Surgery Hospital, Second military medical univercity
- Yu-long Dong
- Department of Oncology, Eastern Hepatobiliary Surgery Hospital, Second military medical univercity
- He-ming Xu
- Department of Oncology, Eastern Hepatobiliary Surgery Hospital, Second military medical univercity
- Lie-ping Guo
- Department of Oncology, Eastern Hepatobiliary Surgery Hospital, Second military medical univercity
- Dong-sheng Chen
- Jiangsu Simcere Diagnostics Co., Ltd, The State Key Laboratory of Translational Medicine and Innovative Drug Development
- Yun-jie Song
- Jiangsu Simcere Diagnostics Co., Ltd, The State Key Laboratory of Translational Medicine and Innovative Drug Development
- Chuang Qi
- Jiangsu Simcere Diagnostics Co., Ltd, The State Key Laboratory of Translational Medicine and Innovative Drug Development
- Wang-long Deng
- Jiangsu Simcere Diagnostics Co., Ltd, The State Key Laboratory of Translational Medicine and Innovative Drug Development
- Zhen-gang Yuan
- Department of Oncology, Eastern Hepatobiliary Surgery Hospital, Second military medical univercity
- DOI
- https://doi.org/10.1038/s41467-023-37030-w
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 14
Abstract
Chemotherapeutic agents and immune checkpoint inhibitors have shown modest efficacy in patients with advanced biliary tract cancers (BTCs). Here the authors report the results of a phase II trial of the anti-PD1 antibody sintilimab plus chemotherapy (gemcitabine and cisplatin) as first-line treatment for patients with advanced BTCs.
